FibroBiologics, Inc. (NASDAQ:FBLG) Shares Purchased by Barclays PLC

Barclays PLC lifted its position in FibroBiologics, Inc. (NASDAQ:FBLG) by 363.2% during the third quarter, HoldingsChannel.com reports. The fund owned 39,958 shares of the company’s stock after acquiring an additional 31,331 shares during the period. Barclays PLC’s holdings in FibroBiologics were worth $123,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in FBLG. The Manufacturers Life Insurance Company acquired a new stake in shares of FibroBiologics in the third quarter worth approximately $32,000. Jane Street Group LLC purchased a new position in FibroBiologics during the third quarter worth approximately $37,000. Mercer Global Advisors Inc. ADV purchased a new position in FibroBiologics during the second quarter worth approximately $51,000. Symphony Financial Ltd. Co. purchased a new position in FibroBiologics during the third quarter worth approximately $76,000. Finally, Rhumbline Advisers purchased a new position in FibroBiologics during the second quarter worth approximately $115,000.

FibroBiologics Trading Down 8.8 %

FBLG stock opened at $2.06 on Thursday. FibroBiologics, Inc. has a 12-month low of $1.08 and a 12-month high of $55.00. The business’s fifty day moving average price is $2.54 and its 200 day moving average price is $3.02.

Analysts Set New Price Targets

FBLG has been the topic of a number of analyst reports. Maxim Group initiated coverage on FibroBiologics in a research report on Tuesday, September 24th. They set a “buy” rating and a $12.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a research report on Wednesday, November 13th. D. Boral Capital restated a “buy” rating and issued a $16.00 target price on shares of FibroBiologics in a research report on Friday, December 27th. Finally, Rodman & Renshaw began coverage on FibroBiologics in a research report on Thursday, December 12th. They issued a “buy” rating and a $12.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.